Ocular Therapeutix Accelerates AXPAXLI NDA Submission for Wet AMD
Event summary
- Ocular Therapeutix plans to submit NDA for AXPAXLI in wet AMD by Q4 2026, following positive Type C meeting with FDA.
- Post-hoc analysis shows up to 72% reduction in treatment burden over 60 weeks with AXPAXLI compared to aflibercept (2 mg).
- Company reports $598.6 million cash balance as of June 30, 2026, with runway into 2028.
- SOL-R trial amended to evaluate superiority to aflibercept (8 mg) at Week 96 and prevention of fibrosis and atrophy.
The big picture
Ocular Therapeutix is advancing its lead candidate, AXPAXLI, through a streamlined regulatory pathway aimed at reducing treatment burden for wet AMD patients. The company's strategic focus on commercial readiness and cash management positions it to capitalize on potential approvals in a competitive ophthalmology market. The amendments to the SOL-R trial reflect Ocular's efforts to differentiate AXPAXLI as a best-in-disease agent, addressing unmet needs in retinal disease treatment.
What we're watching
- Regulatory Pathway
- Whether the FDA's Section 505(b)(2) pathway will accelerate AXPAXLI's review timeline by up to 60 days.
- Commercial Readiness
- The pace at which Ocular Therapeutix can prepare for a potential 2027 launch of AXPAXLI, if approved.
- Clinical Trial Outcomes
- How the amended SOL-R trial will impact AXPAXLI's label potential and market positioning in wet AMD.